Prostacyclin and vascular disease.
We hypothesize that prostacyclin (PGI2) is an anti-atherosclerotic hormone and that atherosclerosis develops when endothelial PGI2 synthetase is inhibited by lipid peroxides. Serum lipid peroxides occur in low-density lipoproteins (LDL). LDL lipid peroxides are elevated in common types of hyperlipoproteinaemias, PGI2 generation is impaired in atherosclerosis, and infusion of synthetic PGI2 into patients alleviates symptoms resulting from arteriosclerosis obliterans, central retinal vein occlusion or spontaneous angina.
D001161:Arteriosclerosis / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D011464:Epoprostenol / Q000502:physiology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008054:Lipid Peroxides / Q000378:metabolism; D008297:Male; D011453:Prostaglandins / Q000627:therapeutic use*; D011465:Prostaglandins, Synthetic / Q000627:therapeutic use; D012160:Retina / Q000098:blood supply; D012164:Retinal Diseases / Q000188:drug therapy
D008054:Lipid Peroxides; D011453:Prostaglandins; D011465:Prostaglandins, Synthetic; D011464:Epoprostenol